

1 Systematic Review

2 **Review and methodological analysis of trials currently testing treatment and**
3 **prevention options for COVID-19 globally.**

4 Paraskevi C. Fragkou^{1,2,§,*}, Drifa Belhadi^{3,4,§}, Nathan Peiffer-Smadja^{3,5,¥}, Charalampos
5 D. Moschopoulos^{1,¥}, François-Xavier Lescure^{3,5}, Hannah Janocha⁶, Emmanouil
6 Karofylakis¹, Yazdan Yazdanpanah^{3,5}, France Mentré^{3,4}, Chrysanthi Skevaki^{2,6},
7 Cédric Laouénan^{3,4,#}, Sotirios Tsiodras^{1,2,#} on behalf of the ESCMID Study Group for
8 Respiratory Viruses.

9 ¹ 4th Department of Internal Medicine, Medical School, National and Kapodistrian
10 University of Athens, Attikon University Hospital, Athens, Greece

11 ² European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
12 Study Group for Respiratory Viruses (ESGREV)

13 ³ Université de Paris, IAME, INSERM, F-75018 Paris, France

14 ⁴ Département d'Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat
15 – Claude-Bernard, AP-HP, 75018 Paris, France

16 ⁵ Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-
17 Publique Hôpitaux de Paris, Paris, France

18 ⁶ Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre
19 (UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL)
20 Marburg, Germany

21 ***Corresponding author:** Paraskevi C. Fragkou, 4th Department of Internal Medicine,
22 Medical School, National and Kapodistrian University of Athens, Attikon University

23 Hospital, Chaidari, Athens, 12462, Greece. Tel: +306973388299, Fax: +30

24 2105326446, Email: evita.fragou@gmail.com.

25 § Equal contribution as first authors

26 ¥ Equal contribution as second authors

27 #Equal contribution as senior authors

28 **Abstract word count:** 294 words

29 **Main manuscript word count:** 3873 words

30

31 **ABSTRACT**

32 **Background:** As COVID-19 cases continue to rise globally within an unprecedented
33 short period of time, solid evidence from large randomised controlled trials is still
34 lacking. Currently, numerous trials testing potential treatment and preventative
35 options are undertaken globally.

36 **Objectives:** We summarised all currently registered clinical trials examining
37 treatment and prevention options for COVID-19. Additionally, we evaluated the
38 quality of the retrieved interventional studies.

39 **Data sources:** Clinicaltrials.gov, the Chinese Clinical Trial Registry and the European
40 Union Clinical Trials Register were systematically searched.

41 **Study eligibility criteria:** Registered clinical trials examining treatment and/or
42 prevention options for COVID-19 were included. No language, country or study
43 design restrictions were applied. We excluded withdrawn or cancelled studies and
44 trials not reporting therapeutic or preventative strategies for COVID-19.

45 **Participants and interventions:** No restrictions in terms of participants' age and
46 medical background or type of intervention were enforced.

47 **Methods:** The registries were searched using the term "coronavirus" or "COVID-19"
48 from their inception until 26th March 2020. Additional manual search of the registries
49 was also performed. Eligible studies were summarised and tabulated. Interventional
50 trials were methodologically analysed, excluding expanded access studies and trials
51 testing Traditional Chinese Medicine.

52 **Results:** In total, 309 trials evaluating therapeutic management options, 23 studies
53 assessing preventive strategies and 3 studies examining both were retrieved.

54 Interventional treatment studies were mostly randomised (n=150, 76%) and open-
55 label (n=73, 37%) with a median number of planned inclusions of 90 (IQR 40-
56 200).Major categories of interventions that are currently being investigated are
57 discussed.

58 **Conclusion:** Numerous clinical trials have been registered since the onset of the
59 COVID-19 pandemic. Summarised data on these trials will assist physicians and
60 researchers to promote patient care and guide future research efforts for COVID-19
61 pandemic containment. However, up to the end of March, 2020, significant
62 information on reported trials was often lacking.

63

64 **Keywords:** SARS-CoV-2; COVID-19; novel coronavirus; pneumonia; treatment;
65 prevention; antivirals; immunomodulators; anti-inflammatory; clinical trials.

66

67 INTRODUCTION

68 COVID-19 pandemic induced by the Severe Acute Respiratory Syndrome
69 coronavirus 2 (SARS-CoV-2) has already affected most countries globally [1]. As of
70 April 12, 2020, more than 1,690,000 COVID-19 cases have been officially reported
71 leading to more than 150,900 deaths worldwide, with numbers constantly rising on a
72 daily basis as the virus continues to spread exponentially [2,3].

73 The original source of SARS-CoV-2 is still debatable, though phylogenetic data
74 analysis converge into the hypothesis that SARS-CoV-2 has possibly originated from
75 bat SARS-like coronaviruses (CoVs) [4–6]. Human CoVs are positive-sense single-
76 stranded RNA (+ssRNA) viruses belonging to the *Orthocoronavirinae* subfamily [7].
77 The analysis of viral genome as well as structural and non-structural proteins plays
78 central role in identifying candidate treatment targets [7]. Notably, the SARS-CoV-2
79 surface spike glycoprotein (S-protein) is a key structural component that controls the
80 viral interaction with hosts' angiotensin I converting enzyme 2 (ACE2) receptor in
81 order to invade human epithelial cells [8]. Moreover, molecules directed against non-
82 structural proteins such as the viral protease or pathways imperative for viral genome
83 replication, alone or along with boosters or regulators of the host's immune system,
84 constitute promising therapeutic strategies[8,9].

85 Given the steep upsurge of COVID-19 cases worldwide within an unprecedented
86 short period of time, we are still waiting for solid evidence from large randomised
87 controlled trials regarding targeted antiviral treatments. In this systematic review, we
88 aim firstly to summarise the data on all currently tested treatment and prevention
89 options for the COVID-19 disease, and secondly to methodologically analyse and
90 evaluate the quality of the registered interventional studies.

91

92 **METHODS**

93 Registered clinical trials were systematically searched at the ClinicalTrials.gov
94 database[10], the Chinese Clinical Trial Registry[11] and the European Union
95 Clinical Trials Register [12] from their inception up to 26th March 2020 using the
96 search terms “coronavirus” or “COVID-19”. Additional manual search of the
97 registries was performed for possibly unidentified studies. No language, country or
98 study design restrictions were applied. Participants of any age and medical
99 background with or at risk for COVID-19 were included, as were any currently tested
100 intervention related to the treatment or prevention of COVID-19.

101 We excluded withdrawn or cancelled studies and trials not reporting therapeutic or
102 preventative measures for COVID-19. Eligible studies were summarised and
103 tabulated.

104 Methodological analysis of the interventional studies was performed. Traditional
105 Chinese Medicine (TCM) and homeopathy were excluded from the in-depth
106 qualitative assessment, as we have no expertise to analyse clinical trials testing these
107 agents that rely on controversial scientific rationale [13,14]. We evaluated the study
108 design, number of planned inclusions and primary outcomes of interventional studies,
109 excluding retrospective and “expanded access” studies. Studies were also analysed
110 according to their primary endpoint, i.e. clinical, virological (viral excretion in clinical
111 samples), radiological (imaging results such as CT-scan or X-rays), or biological /
112 immunological (complete blood count, CR, CD8+/CD4+ T cells count, etc.). This
113 review was conducted according to the PRISMA guidelines [15].

114

115 RESULTS

116 1. General data retrieved

117 In total, 335 studies were retrieved, including 309 trials evaluating therapeutic
118 molecules, devices and other management options, 23 studies assessing medications,
119 vaccines under development and other preventive strategies, and 3 studies examining
120 both (Figure 1, Table S1, Table S2). An overview of currently tested therapeutic
121 interventions is presented in Figure 2 and Figure 3.

122

123 2. Main treatment interventions

124

125 Protease Inhibitors

126 Lopinavir is a protease inhibitor (PI) active against human immunodeficiency virus 1
127 (HIV-1) infection. The main coronavirus proteinase (3C-like proteinase or 3CL^{pro})
128 plays a key role in processing viral polyproteins [16,17]. PIs effectively inhibit the
129 3CL^{pro} enzyme, thus posing a possibly potent therapeutic agent against SARS-CoV-2
130 infection.

131 PIs have shown effectiveness against SARS-CoV, MERS-CoV and SARS-CoV-2
132 viruses in *in vitro* susceptibility models [18–21]. During SARS-CoV epidemic,
133 lopinavir boosted by ritonavir (a cytochrome P450-3A4 inhibitor) with or without
134 ribavirin, significantly reduced adverse outcomes including mortality[22]. The
135 MIRACLE trial that examines the efficacy of ritonavir boosted lopinavir combined
136 with recombinant interferon-beta 1b (IFN-β1b) in the treatment of MERS, is currently
137 undertaken in Saudi Arabia and results are pending [23].

138 For COVID-19, lopinavir/ritonavir combined with or without other agents has been
139 reported to successfully reduce adverse outcomes in sporadic cases from China [24–
140 27]. These promising reports have set the ground for numerous trials addressing the
141 safety and efficacy of PIs in SARS-CoV-2 infection (Table 1). Other PIs that are
142 currently being assessed are ritonavir boosted ASC09 (a novel PI), cobicistat boosted
143 darunavir as well as the NS3/4A protease inhibitor danoprevir combined with
144 ritonavir (Table 1, Table S1).

145

146 **RNA polymerase inhibitors**

147 SARS-CoV-2 and SARS-CoV RNA-dependent RNA polymerase (RdRp) share 96%
148 sequence identity; this has justified the assumption that inhibitors effective against
149 SARS-CoV could have similar inhibitory effects against SARS-CoV-2[28].
150 Nucleoside analogues compete with natural nucleosides for the RdRp active site, thus
151 inhibiting the viral genome replication [29].Current research efforts focus on
152 repurposing older moleculesinCOVID-19 treatment, as their safety profile has already
153 been documented [30].

154 Remdesivir (GS-5734TM) is an adenosine analogue with broad-spectrum antiviral
155 properties [31]. Preclinical data demonstrated the efficacy of remdesivir against
156 SARS-CoV and MERS-CoV, as it has the potential to outcompete the proofreading
157 ability of coronavirus exonuclease, and carries a high genetic resistance barrier
158 [21,28,30,32]. Wang et al. confirmed its *in vitro* efficacy against SARS-CoV-2
159 [33].Currently, it is investigated in 7 randomised, controlled trials (Table 1, Table S1).

160 Favipiravir is a nucleoside analogue inhibiting the RNA polymerase, initially
161 approved for the treatment of novel influenza viruses [34]. It is also effective against a

162 broad range of viruses, including positive-sense single-stranded RNA viruses [34].
163 Since there have been some promising *in vitro* results for its efficacy against SARS-
164 CoV-2, favipiravir is now being investigated in 8 clinical trials.

165 Ribavirin is a guanosine analogue that inhibits inosine monophosphate dehydrogenase
166 required for the synthesis of guanosine triphosphate, leading to lethal mutagenesis of
167 RNA genome [35]. Ribavirin was used in SARS epidemic in combination with either
168 lopinavir/ritonavir or interferon alpha (IFN- α), and these combinations are currently
169 recommended by the China National Practice Guidelines for the treatment of severe
170 COVID-19 [22,36].

171 Azvudine, an azidocytidine analogue that inhibits viral reverse transcriptase, has been
172 effective against HIV, hepatitis B and C viruses [37]. Its efficacy against SARS-CoV-
173 2 is being tested in 3 ongoing clinical trials (Table 1, Table S1). Another nucleoside
174 analogue undergoing investigation for COVID-19 pneumonia is
175 emtricitabine/tenofovir alafenamide.

176

177 **Anti-malaria drugs**

178 Chloroquine and hydroxychloroquine are currently licensed for the treatment of
179 malaria and autoimmune diseases [38]. However, they have also been studied against
180 several viruses with promising *in vitro* results, never confirmed in humans [39–41].
181 As weak bases, they are concentrated in acidic intra-cellular organelles, leading to
182 alkalization and distraction of the low pH-dependent steps of viral replication,
183 including viral-cell fusion and uncoating [38,40]. Moreover, they impair the terminal
184 glycosylation of ACE2 receptor in Golgi apparatus, thus inhibiting the viral
185 penetration into the host cells [42].

186 As they are accumulated in lymphocytes and macrophages, these drugs reduce
187 secretion of proinflammatory cytokines, and particularly of tumour necrosis factor
188 alpha (TNF- α) [41]. Experimental data demonstrated that chloroquine is highly
189 effective *in vitro* against SARS-CoV-2 in an estimated effective concentration that is
190 easily achievable with standard dosing regimens [33]. Preliminary results from small
191 studies suggested the effectiveness of chloroquine, alone or combined with
192 azithromycin, in viral clearance, inhibition of pneumonia exacerbation, improvement
193 of lung imaging and shortening of the disease course [43,44]. However, clinical trials
194 with a control group are needed to provide reliable answers for clinicians.

195

196 **Immunomodulators and anti-inflammatory drugs**

197 Virus-induced exuberant immune response leading to cytokine storm syndrome (CSS)
198 and secondary haemophagocytic lymphohistiocytosis (HLH) is probably the
199 underlying pathogenetic mechanism that leads to critical and often fatal COVID-19
200 infection [45,46]. Hyperinflammation is associated with acute respiratory distress
201 syndrome (ARDS) and fulminant multi-organ failure that is fatal if left untreated. In
202 this context, immunosuppressors (along with antivirals) may play a key role in
203 counteracting severe SARS-CoV-2 infection [45].

204 Preliminary data from COVID-19 patients in China reported significantly higher
205 interleukin (IL)-6 levels in patients with critical COVID-19 disease than those with
206 severe or mild disease [47]. Tocilizumab and sarilumab, both humanised monoclonal
207 antibodies (mAbs) against the IL-6 receptor, are currently evaluated in 14 clinical
208 trials (Table 1, Table S1); tocilizumab, in particular, improved symptoms and
209 laboratory parameters in a small retrospective study in China [48]. Various other

210 molecules oriented against different cytokines, as well as intra- and extra-cellular
211 inflammatory pathways, are currently being tested in COVID-19 including:
212 adalimumab, anti-programmed cell death protein 1 mAbs, bevacizumab, ixekizumab,
213 eculizumab, human recombinant IL-2, inhibitors of NLRP3 inflammasome activation
214 (tranilast), Janus Kinase inhibitors, fingolimod and a recombinant fusion protein
215 targeting an immune pathway checkpoint (CD24Fc).Clinical trials on other
216 immunotherapies (i.e.gimsilumab, siltuximab, lenzilumab and leronlimab) have been
217 proposed, but havenot been registered yet.

218 Immunomodulators licensed for haematological and rheumatological conditions (such
219 as leflunomide and thalidomide), as well as colchicine that counteracts the assembly
220 of the NLRP3 inflammasome, are also being studied for their therapeutic use against
221 SARS-CoV-2 (Table 1,Table S1) [49].

222 The immunomodulatory effects of macrolide antibiotics, as well as their
223 pharmacodynamic property to achieve at least 10-fold higher concentrations in
224 epithelial lung fluid than in serum, have led researchers to repurpose them against
225 SARS-CoV-2 (Table 1, Table S1) [50,51]. Preliminary results of a study have
226 shownsignificant viral load reduction in patients treated withhydroxychloroquine plus
227 azithromycin [43].

228 Corticosteroids are major anti-inflammatory drugs, with a conflicting safety profile in
229 severe viral infections [52]. However, their useis currently recommended by the
230 European Society of Intensive Care Medicine in COVID-19 cases with shock and/or
231 evidence of CSS/HLH and/or mechanically ventilated patients with ARDS [53].
232 Corticosteroids are being tested in 11 clinical trials (Table 1, Table S1).

233 Finally, immunostimulatory molecules that enhance the hosts' immune response
234 against the invading pathogen, like IFN- α , interferon beta (IFN- β), the recombinant
235 protein produced by DNA-shuffling of IFN- α (novaferon), the inactivated
236 *Mycobacterium* vaccine and thymosin a1, are evaluated as viable therapeutic options
237 in various combinations against SARS-CoV-2 [54].

238

239 **Membrane fusion inhibitors and inhibitors of ACE2 receptor connection**

240 SARS-CoV-2S-protein bindsACE2 receptor on the epithelial cells' membrane [55].
241 The host's type II transmembrane serine protease (TMPRSS2) facilitates membrane
242 fusion and augments viral internalization by cleaving and activating the S-protein
243 [56,57]. These proteins, being an integral part of the viral life cycle, can be used as
244 possible therapeutic targets.

245 ACE inhibitors (ACEi) selectively inhibit ACE1 but not ACE2, as they are
246 structurally different enzymes [58]. Experimental animal models show that
247 angiotensin II type 1 receptor blockers (ARBs) and ACEi may up-regulate ACE2
248 expression; although this raised concerns that ACEi and ARBs may be associated
249 with a more severe form of COVID-19, there is no evidence supporting that ACE2
250 up-regulation augments the virulence or the penetration of the virus into the hosts'
251 cells as of yet [58,59]. Contrarily, renin-angiotensin system (RAS) inhibition may
252 ameliorate the over-accumulation of angiotensin II induced by the down-regulation of
253 ACE2 noted in other CoVs infection, thus possibly protecting against the
254 development of fulminant myocarditis and ARDS [58]. In spite of controversial data,
255 2 randomised controlled trialstesting losartan are currently undertaken in the USA.

256 Camostat mesilate is a potent serine protease inhibitor, inhibiting the TMPRSS2 and
257 is approved for chronic pancreatitis [60]. *In vitro* experiments have shown that
258 camostat is effective against SARS-CoV-2[61]. Nafamostat, another inhibitor of
259 TMPRSS2 has been suggested in COVID-19 therapy, but no registered trials are
260 available yet.

261 Umifenovir is a small indole derivative with a broad-spectrum antiviral activity
262 developed about 30 years ago [62,63]. Although it is currently used in Russia and
263 China to combat influenza, it has shown *in vitro* activity against numerous DNA and
264 RNA viruses including SARS-CoV [62,64,65]. It primarily targets the interaction
265 between viral capsid and the membrane of the host cell by inhibiting the attachment,
266 the fusion and the internalization of the virus [62]. Moreover, umifenovir has direct
267 virucidal effects against enveloped viruses through interaction with the viral lipid
268 envelope or with key residues within structural proteins of virions [62,65,66]. Limited
269 data support that umifenovir may exhibit immunomodulatory effects by stimulating
270 hosts' humoral immune response, interferon production, and phagocytes' activation
271 [67]. A small retrospective study in China demonstrated some promising results
272 regarding its effectiveness against SARS-CoV-2 when used in combination with
273 lopinavir/ritonavir [68]. Currently 11 relevant clinical trials are in progress globally
274 (Table 1, Table S1).

275

276 **Passive immunization**

277 The use of convalescent plasma (CP) to passively immunise patients against viral
278 pathogens has been previously reported, especially when no other treatment options
279 were available [69]. CP obtained from recovering patients was used during the SARS

280 epidemic; two retrospective studies demonstrated that CP administration in SARS
281 patients reduced duration of hospitalisation and mortality rates, when treatment with
282 ribavirin and corticosteroids failed [70–72].

283 A meta-analysis of patients with severe respiratory infection induced by various
284 viruses showed a statistically significant reduction of 75% in mortality odds in those
285 who received CP across all viral aetiologies, including the influenza A 2009 pandemic
286 strain (H1N1pdm09) and SARS-CoV[73]. Evidence of survival benefit was noted
287 after early administration, while no serious adverse effects were reported. Although
288 results are pending from 10 relevant clinical trials, the potential short-lasting
289 immunity after CoV infection has raised uncertainty regarding the clinical efficacy of
290 CP antibodies in clinical practice[74,75].

291

292 **Cell therapies**

293 Mesenchymal stromal cells (MSCs) exhibit immunomodulating qualities, may skew
294 immune cell differentiation and have shown promise in H5N1-associated acute lung
295 injury in preclinical models[76]. A pilot study involving MSC transplantation in 7
296 patients with COVID-19 resulted in cure or significant improvement of pulmonary
297 function and symptoms without adverse effects [77]. MSCs may partially accumulate
298 in lungs and improve the pulmonary microenvironment. A significant induction of
299 regulatory dendritic cells(DCs), along with a shift from Th1 towards Th2 immune
300 responses, was also observed [77]. Other clinical trials utilizing MSCs for curing
301 COVID-19 are ongoing (Table 1, Table S1).

302 MSC-derived exosomes are extracellular bodies mediating intercellular
303 communication, containing mRNAs, miRNAs, lipids, growth factors and cytokines,

304 that possibly exert the paracrine immunoregulatory effects of MSC [78]. Furthermore,
305 MSC-exosomes' administration is associated with lower risks (e.g.tumour formation,
306 immunogenicity) compared to the intravenous injection of MSCs [79].

307 Natural killer cells have shown promising results as adoptive immunotherapy in
308 various cancers, and may also be potent effector cells in the SARS-CoV-2 infection.
309 A phase 1 clinical trial has been launched to determine their efficacy (Table S1).
310 Lastly, ozone therapy may inactivate viruses, among other pathogens, and activate the
311 immune system via up-regulation of Th1 cytokines including IFN and TNF; as such,
312 trials have been launched to evaluate ozone autohaemotherapy efficacy in COVID-19
313 [80].

314

315 **3. Main preventative measures**

316 The World Health Organization (WHO) and the European Centre for Disease
317 Prevention and Control (ECDC) emphasise the role of screening, precaution
318 measures, exposure prevention and environmental disinfection as the mainstay of
319 COVID-19 prevention[81,82]. As no effective preventative options are available yet,
320 several clinical trials are under way to explore the efficacy of various prevention
321 strategies (Table 2, Table S2).

322 Many studies are currently evaluating the efficacy of TCM in COVID-19 prevention
323 in China. Importantly, at least 4 vaccines are under development. Among them, an
324 mRNA-based vaccine encoding the S-protein is being assessed for its safety,
325 reactogenicity and efficacy against SARS-CoV-2 (Table 2, Table S2). Besides the
326 registered trials, other large companies have also announced the initiation of vaccine
327 development [83,84].

328 Other preventative molecules include hydroxychloroquine and the recombinant
329 human interferon α 1b spray. In the USA, exposed individuals are randomised to
330 hydroxychloroquine or placebo, evaluating the agent's potential as post-exposure
331 prophylaxis (NCT04308668, Table S2). Furthermore, another randomised clinical
332 trial evaluates the efficacy of a 3-month course of chloroquine in at-risk healthcare
333 personnel (NCT04303507, Table S2). Finally, the live attenuated strain of
334 *Mycobacterium bovis* is expected to be tested as a preventative strategy against
335 COVID-19 among healthcare professionals, in Australia and France.

336

337 **4. Methodological analysis of interventional studies**

338 **Study Populations**

339 In total, 198 interventional treatment and 16 prevention trials were included in the
340 methodological analysis respectively (Table 3). Among the eligible treatment studies,
341 children recruitment (i.e. < 14 years old) was reported in 7 clinical trials in total: 1
342 testing darunavir with cobicistat (NCT04252274); 2 on human stem cells transfusion
343 (ChiCTR2000029606, ChiCTR2000030944); 1 testing hydroxychloroquine
344 (EudraCT Number: 2020-000890-25); 1 using tocilizumab (NCT04317092); and 1
345 assessing nutritional supplements (NCT04323345) (Table S1). With respect to
346 relevant prevention studies, children were included in 2 vaccine
347 trials (NCT04276896 and NCT04299724) as shown in Table S2.

348

349 **Study designs**

350 Phase IV and phase III treatment trials were the most commonly reported
351 interventional study types (n=40, 20% and n=35, 18% respectively) as demonstrated
352 in Table 3. Nonetheless, the majority of registered trials do not disclose the study
353 phase (n=83, 42%).

354 In terms of blinding, 73 open-label (37%), 31 double-blinded (16%), and 16 single-
355 blinded (8%) studies were retrieved. Most trials were randomised (n=150, 76%) with
356 a parallel assignment between arms. The median (IQR) number of planned inclusions
357 is 90 (40-200) with a range of 5 to 6000 participants.

358 Phase III and phase I prevention studies were the most commonly reported ones (n=6,
359 38% and n=3, 19% respectively, Table3). As with treatment trials, many prevention
360 trials do not report the study phase (n=4, 25%).

361 Regarding prevention studies' blinding, 6double-blinded (38%), 5open-label (31%),
362 and 2 single-blinded (13%) were found. Most studies were randomised (n=10, 63%)
363 with a parallel assignment design. The median (IQR) number of planned inclusions is
364 513 (177-2958) ranging from 45 to 7576 participants.

365

366 **Treatments and interventions**

367 Various types of interventions are currently evaluated; however, their appraisal is
368 limited by the lack of reported data concerning the treatment dose and duration.
369 Figure 4 demonstrates the number of trials by the median of planned inclusions per
370 trial for the ten most frequently encountered therapies. Although remdesivir is tested
371 in only 7 trials, these studies have the highest median number of planned inclusions
372 per trial (453, IQR 397-650). On the other hand, cell therapies are assessed by the

373 highest number of trials (n=25), but with a disproportionately low median number of
374 planned inclusions (30, IQR 20-60). Figure 5 shows the total number of planned
375 inclusions and the number of clinical trials for the ten most frequently studied
376 treatments, with hydroxychloroquine being the treatment associated with the highest
377 total number (10,146 planned inclusions).

378

379 **Primary endpoints and outcomes**

380 A clinical primary outcome was defined in 128 therapeutic trials (65%; Table 3); most
381 of them focused on the symptoms' evolution such as time to clinical recovery, the
382 proportion of patients with clinical improvement or deterioration, length of
383 hospitalisation or mortality. A number of scores are utilized as primary outcomes such
384 as the ordinal 7-point scale adapted from the WHO master protocol, the lung injury
385 score, the pneumonia severity index or the National Early Warning Score 2 score [85–
386 87]. Most prevention studies disclose a clinical primary outcome (13 studies, 81%),
387 while virological, radiological and biological/immunological primary endpoints were
388 reported in 39 (20%), 19 (10%), and 12 (6%) studies respectively (Table 3).

389

390 **DISCUSSION**

391 The SARS-CoV-2 is the third emerging coronavirus of the last 20 years, but the one
392 that has led to an evolving pandemic, a fact that urgently requires the implementation
393 of novel therapeutics. However, repurposing of existing drugs is a viable and less
394 time-consuming alternative; licensed broad-spectrum antiviral agents with a well-
395 documented safety profile are currently tested against SARS-CoV-2. Alternatively,

396 screening of chemical compounds' libraries may be useful in the discovery of an
397 efficacious treatment against COVID-19 disease [8]. In this review, we have
398 summarised and methodologically appraised the ongoing therapeutic and preventive
399 trials for COVID-19.

400 Therapeutic strategies should follow the two-phased immune response to COVID-19.
401 Initially, treatment should aim at strengthening the host's immune response against the
402 virus, and inhibiting the viral replication [88]. Early initiation of antiviral therapy has
403 been proved beneficial for the prognosis of patients[89]. As advanced age correlates
404 with higher viral loads, older patients could strongly benefit from the prompt
405 initiation of antivirals[90]. Moreover, high inflammatory cytokine levels have been
406 correlated with disease severity and the extent of lung damage[91]. Thus, in the later
407 phase of the infection, patients could be availed by anti-inflammatory therapeutic
408 approaches such as the Janus kinase inhibitors, blood purification or tocilizumab
409 [92,93].

410 The Chinese National Health Commission recommends antiviral therapy with the
411 protease inhibitors lopinavir/ritonavir. Other recommended antiviral agents include
412 interferon alpha and chloroquine phosphate [93]. Advantages of chloroquine include
413 its long clinical history, known side effects and low cost, which render it a good
414 candidate for global use[33]. The broad-spectrum antiviral agent remdesivir has
415 successfully been used in individual COVID-19 cases by the Washington Department
416 of Health[94]. Effectiveness of both chloroquine and remdesivir against COVID-19
417 remains to be seen in ongoing trials.

418 Prevention is a key player in combating pandemics. The mRNA 1273 vaccine, is
419 currently in phase I, but is not expected to be commercially available this year[95].

420 The prophylactic potential of hydroxychloroquine/chloroquine is also actively being
421 examined among healthcare professionals[96]. Moreover, prompt testing and isolation
422 are of utmost importance for disease prevention. At the moment, real-time
423 quantitative polymerase chain reaction is the reference standard in diagnostics [97].
424 The FDA has recently announced the authorisation of rapid molecular tests that are
425 capable of delivering results within minutes, thus facilitating early treatment
426 initiation(when viral loads are highest) and timely isolation[90,98,99].

427 Based on the retrieved data, cell therapies and hydroxychloroquine were the most
428 frequently evaluated candidate therapies (25 and 22 trials respectively), while
429 remdesivir was associated with the highest median number of planned inclusions per
430 trial (453, IQR 397-650).Although TCMs and homeopathy represent a large
431 proportion of the identified interventional studies, we excluded them from our
432 methodological analysis as we do not have the expertise to analyse clinical trials
433 testing these agents.

434 This review shows the considerable amount of clinical trials that are currently
435 registered. Although the number of identified trials was high, there were several
436 methodological caveats. Firstly, study design data and details on the interventions
437 being assessed were often lacking. This hampers the available information to
438 researchers and relevant stakeholders, and potentially influences the discovery of
439 successful treatments.

440 Secondly, most trials, and especially those registered at the beginning of the
441 pandemic, disclosed low participant numbers, which may impact the robustness of
442 their future results. However, these numbers should be cautiously interpreted, as they
443 represent the anticipated, and not the actual number of inclusions. Thirdly, reported

444 primary endpoints were highly heterogeneous among studies. In our opinion, the
445 application of clinical primary endpoints should be encouraged in an infection where
446 the association between the clinical status and viral clearance, radiological or
447 immunological evolution is obscure.

448 The identification of the best therapeutic approach is challenging, especially in the
449 context of a pandemic with thousands of casualties. Our study underlines the need to
450 meticulously register as many study details as possible on international registries
451 during outbreaks, in order to guide the development and enhance the consistency of
452 future trials. The development of clinical trials during an outbreak is an adaptive
453 process and new evidence emerges at an impressive rate. A review of the early
454 registered clinical trials is an important asset for researchers and methodologists.
455 These results might encourage transparency when developing and registering future
456 clinical trials and help improve their methodology, hence the robustness of their
457 results.

458 In the absence of reliable vaccines and therapies, disease containment plays a pivotal
459 role, as has been recently observed in China. Undertaking actions such as nationwide
460 temperature measurements, health recommendations, detection and strict isolation
461 proved to slow down the transmission rate [100]. The time thereby won is precious
462 for the development of therapies and vaccines. This approach is especially useful for
463 countries with weaker health systems that lack sufficient medical supplies and
464 infrastructure, and often depend on the support of the international community.

465

466 **Transparency declaration**

467 *Conflict of interest:* For YY: Chair of the Global Research Collaboration for
468 Infectious Disease Preparedness (GloPID-R) and the coordinator of REsearch and
469 ACTion targeting emerging infectious diseases (REACTing).

470 For CS: Consultancy and research funding, Hycor Biomedical and Thermo Fisher
471 Scientific; Consultancy, BencardAllergie; Research Funding, Mead Johnson Nutrition
472 (MJN). Supported by Universities Giessen and Marburg Lung Centre (UGMLC), the
473 German Centre for Lung Research (DZL), University Hospital Giessen and Marburg
474 (UKGM) research funding according to article 2, section 3 cooperation agreement,
475 and the Deutsche Forschungsgemeinschaft (DFG)-funded-SFB 1021 (C04), -KFO
476 309 (P10), and SK 317/1-1 (Project number 428518790). All grants are outside the
477 submitted work.

478 *Funding:* No external funding was received for this study.

479 *Author contributions:* Conception and design: PCF, ST, DB, NPS, FM, CL.
480 Acquisition of data: PCF, EK, CDM, HJ, CS, DB, NPS, YY. Interpretation of data: all
481 authors. Drafting the article: PCF, EK, CDM, HJ, CS, DB, NPS, FM, CL, YY.
482 Revising critically the manuscript for important intellectual content: PCF, CS, ST.
483 PCF and DB contributed equally as first authors, CDM and NPS contributed equally
484 as second authors, CL and ST contributed equally as senior authors. All authors
485 approved the final version of the manuscript submitted.

486

487 **REFERENCES**

- 488 [1] Interim Guidance: Healthcare Professionals 2019-nCoV | CDC n.d.
489 <https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html>
490 (accessed April 2, 2020).

- 491 [2] Situation reports n.d. <https://www.who.int/emergencies/diseases/novel->
492 [coronavirus-2019/situation-reports/](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/) (accessed April 2, 2020).
- 493 [3] Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in
494 the EU/EEA and the UK – seventh update. n.d.
- 495 [4] Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G,
496 Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-
497 nCoV) rejects the hypothesis of emergence as a result of a recent
498 recombination event. *Infect Genet Evol* 2020;79:104212.
499 <https://doi.org/10.1016/j.meegid.2020.104212>.
- 500 [5] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
501 epidemiology of 2019 novel coronavirus: implications for virus origins and
502 receptor binding. *Lancet* 2020;395:565–74. <https://doi.org/10.1016/S0140->
503 [6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8).
- 504 [6] Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M.
505 The 2019-new coronavirus epidemic: Evidence for virus evolution. *J Med*
506 *Viro* 2020;92:455–9. <https://doi.org/10.1002/jmv.25688>.
- 507 [7] Harrison C. Coronavirus puts drug repurposing on the fast track. *Nat*
508 *Biotechnol* 2020. <https://doi.org/10.1038/d41587-020-00003-1>.
- 509 [8] Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV).
510 *Biosci Trends* 2020;14:69–71. <https://doi.org/10.5582/bst.2020.01020>.
- 511 [9] Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A
512 systematic review. *J Med Viro* 2020;92:479–90.
513 <https://doi.org/10.1002/jmv.25707>.
- 514 [10] Home - ClinicalTrials.gov n.d. <https://clinicaltrials.gov/> (accessed April 2,
515 2020).
- 516 [11] Chinese Clinical Trial Register (ChiCTR) - The world health organization

517 international clinical trials registered organization registered platform n.d.
518 <http://www.chictr.org.cn/searchprojen.aspx> (accessed April 2, 2020).

519 [12] EU Clinical Trials Register - Update n.d. <https://www.clinicaltrialsregister.eu/>
520 (accessed April 2, 2020).

521 [13] Hard to swallow. *Nature* 2007;448:105–6. <https://doi.org/10.1038/448106a>.

522 [14] Ernst E. Homeopathy, a “helpful placebo” or an unethical intervention? *Trends*
523 *Pharmacol Sci* 2010;31:1. <https://doi.org/10.1016/j.tips.2009.10.005>.

524 [15] Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al.
525 Preferred reporting items for systematic reviews and meta-analyses: The
526 PRISMA statement. *PLoS Med* 2009;6.
527 <https://doi.org/10.1371/journal.pmed.1000097>.

528 [16] Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, et al. α -Ketoamides as
529 Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication:
530 Structure-Based Design, Synthesis, and Activity Assessment. *J Med Chem*
531 2020. <https://doi.org/10.1021/acs.jmedchem.9b01828>.

532 [17] Fan K, Wei P, Feng Q, Chen S, Huang C, Ma L, et al. Biosynthesis,
533 purification, and substrate specificity of severe acute respiratory syndrome
534 coronavirus 3C-like proteinase. *J Biol Chem* 2004;279:1637–42.
535 <https://doi.org/10.1074/jbc.M310875200>.

536 [18] Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S.
537 Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-
538 CoV 3CL(pro) inhibitors. *J Theor Biol* 2008;254:861–7.
539 <https://doi.org/10.1016/j.jtbi.2008.07.030>.

540 [19] Chen F, Chan KH, Jiang Y, Kao RYT, Lu HT, Fan KW, et al. In vitro
541 susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral
542 compounds. *J Clin Virol* 2004;31:69–75.

- 543 <https://doi.org/10.1016/j.jcv.2004.03.003>.
- 544 [20] de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van
545 Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound
546 library identifies four small-molecule inhibitors of Middle East respiratory
547 syndrome coronavirus replication in cell culture. *Antimicrob Agents*
548 *Chemother* 2014;58:4875–84. <https://doi.org/10.1128/AAC.03011-14>.
- 549 [21] Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al.
550 Comparative therapeutic efficacy of remdesivir and combination lopinavir,
551 ritonavir, and interferon beta against MERS-CoV. *Nat Commun* 2020;11:222.
552 <https://doi.org/10.1038/s41467-019-13940-6>.
- 553 [22] Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al.
554 Role of lopinavir/ritonavir in the treatment of SARS: initial virological and
555 clinical findings. *Thorax* 2004;59:252–6.
556 <https://doi.org/10.1136/thorax.2003.012658>.
- 557 [23] Arabi YM, Allothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et
558 al. Treatment of Middle East Respiratory Syndrome with a combination of
559 lopinavir-ritonavir and interferon- β 1b (MIRACLE trial): study protocol for a
560 randomized controlled trial. *Trials* 2018;19:81. [https://doi.org/10.1186/s13063-](https://doi.org/10.1186/s13063-017-2427-0)
561 [017-2427-0](https://doi.org/10.1186/s13063-017-2427-0).
- 562 [24] Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. [Management of corona virus
563 disease-19 (COVID-19): the Zhejiang experience]. *Zhejiang Da Xue Xue Bao*
564 *Yi Xue Ban* 2020;49:0.
- 565 [25] Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical
566 diagnosis and treatment of a case infected with coronavirus disease 2019. *J*
567 *Med Virol* 2020;92:461–3. <https://doi.org/10.1002/jmv.25711>.
- 568 [26] Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index

569 patient who caused tertiary transmission of coronavirus disease 2019 in Korea:
570 The application of lopinavir/ritonavir for the treatment of COVID-19
571 pneumonia monitored by quantitative RT-PCR. *J Korean Med Sci* 2020;35.
572 <https://doi.org/10.3346/jkms.2020.35.e79>.

573 [27] Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and
574 therapeutic procedure for four cases with 2019 novel coronavirus pneumonia
575 receiving combined Chinese and Western medicine treatment. *Biosci Trends*
576 2020;14:64–8. <https://doi.org/10.5582/bst.2020.01030>.

577 [28] Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent
578 Prevention and Treatment Options for Severe Acute Respiratory Infections
579 Caused by 2019-nCoV. *Chembiochem* 2020;21:730–8.
580 <https://doi.org/10.1002/cbic.202000047>.

581 [29] Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
582 *Life Sci* 2020;248:117477. <https://doi.org/10.1016/j.lfs.2020.117477>.

583 [30] Martinez MA. Compounds with therapeutic potential against novel respiratory
584 2019 coronavirus. *Antimicrob Agents Chemother* 2020:1–18.
585 <https://doi.org/10.1128/AAC.00399-20>.

586 [31] Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al.
587 Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in
588 rhesus monkeys. *Nature* 2016;531:381–5. <https://doi.org/10.1038/nature17180>.

589 [32] Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al.
590 Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated
591 by the Viral Polymerase and the Proofreading Exoribonuclease. *MBio* 2018;9.
592 <https://doi.org/10.1128/mBio.00221-18>.

593 [33] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and
594 chloroquine effectively inhibit the recently emerged novel coronavirus (2019-

595 nCoV) in vitro. *Cell Res* 2020;30:269–71. [https://doi.org/10.1038/s41422-020-](https://doi.org/10.1038/s41422-020-0282-0)
596 0282-0.

597 [34] Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure
598 against neglected and emerging RNA viruses. *Antiviral Res* 2018;153:85–94.
599 <https://doi.org/10.1016/j.antiviral.2018.03.003>.

600 [35] Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS:
601 A new trick for an old drug? *CMAJ* 2003;168:1289–92.

602 [36] Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the
603 Epidemiological, Clinical, Preventive and Therapeutic Evidence and
604 Guidelines of Integrative Chinese–Western Medicine for the Management of
605 2019 Novel Coronavirus Disease. *Am J Chin Med* 2020:1–26.
606 <https://doi.org/10.1142/s0192415x20500378>.

607 [37] Wang R-R, Yang Q-H, Luo R-H, Peng Y-M, Dai S-X, Zhang X-J, et al.
608 Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug
609 combination features and better inhibition on drug-resistant strains than
610 lamivudine in vitro. *PLoS One* 2014;9:e105617.
611 <https://doi.org/10.1371/journal.pone.0105617>.

612 [38] Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl
613 analogue to face bacterial, fungal and viral infections in the 21st century. *Int J*
614 *Antimicrob Agents* 2007;30:297–308.
615 <https://doi.org/10.1016/j.ijantimicag.2007.05.015>.

616 [39] Touret F, de Lamballerie X. Of chloroquine and COVID-19. *Antiviral Res*
617 2020;177. <https://doi.org/10.1016/j.antiviral.2020.104762>.

618 [40] Colson P, Rolain J-M, Raoult D. Chloroquine for the 2019 novel coronavirus
619 SARS-CoV-2. *Int J Antimicrob Agents* 2020;55:105923.
620 <https://doi.org/10.1016/j.ijantimicag.2020.105923>.

- 621 [41] Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Antiviral effects of
622 chloroquine Effects of chloroquine on viral infections : an old drug against
623 today ' s diseases ? *Lancet* 2003;3:722–7. [https://doi.org/10.1016/S1473-](https://doi.org/10.1016/S1473-3099(03)00806-5)
624 [3099\(03\)00806-5](https://doi.org/10.1016/S1473-3099(03)00806-5).
- 625 [42] Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the
626 antiviral effects of chloroquine. *Lancet Infect Dis* 2006;6:67–9.
627 [https://doi.org/10.1016/S1473-3099\(06\)70361-9](https://doi.org/10.1016/S1473-3099(06)70361-9).
- 628 [43] Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.
629 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of
630 an open-label non-randomized clinical trial. *Int J Antimicrob Agents*
631 2020:105949. <https://doi.org/10.1016/j.ijantimicag.2020.105949>.
- 632 [44] Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown
633 apparent efficacy in treatment of COVID-19 associated pneumonia in clinical
634 studies. *Biosci Trends* 2020;14:72–3. <https://doi.org/10.5582/bst.2020.01047>.
- 635 [45] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al.
636 COVID-19: consider cytokine storm syndromes and immunosuppression.
637 *Lancet (London, England)* 2020;395:1033–4. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(20)30628-0)
638 [6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0).
- 639 [46] Chen C, Zhang XR, Ju ZY, He WF. [Advances in the research of cytokine
640 storm mechanism induced by Corona Virus Disease 2019 and the
641 corresponding immunotherapies]. *Zhonghua Shao Shang Za Zhi* 2020;36:E005.
642 <https://doi.org/10.3760/cma.j.cn501120-20200224-00088>.
- 643 [47] Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical
644 features of 29 patients with 2019 novel coronavirus pneumonia]. *Zhonghua Jie*
645 *He He Hu Xi Za Zhi* 2020;43:203–8. [https://doi.org/10.3760/cma.j.issn.1001-](https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.013)
646 [0939.2020.03.013](https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.013).

- 647 [48] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective Treatment of
648 Severe COVID-19 Patients with Tocilizumab. n.d.
- 649 [49] Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to decrease
650 NLRP3-activated inflammation and improve obesity-related metabolic
651 dysregulation. *Med Hypotheses* 2016;92:67–73.
652 <https://doi.org/10.1016/j.mehy.2016.04.039>.
- 653 [50] Min J-Y, Jang YJ. Macrolide therapy in respiratory viral infections. *Mediators
654 Inflamm* 2012;2012:649570. <https://doi.org/10.1155/2012/649570>.
- 655 [51] Kanoh S, Rubin BK. Mechanisms of action and clinical application of
656 macrolides as immunomodulatory medications. *Clin Microbiol Rev*
657 2010;23:590–615. <https://doi.org/10.1128/CMR.00078-09>.
- 658 [52] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
659 corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020;395:473–5.
660 [https://doi.org/10.1016/S0140-6736\(20\)30317-2](https://doi.org/10.1016/S0140-6736(20)30317-2).
- 661 [53] Important Announcement of new SSC Guidelines – COVID-19 - ESICM n.d.
662 <https://www.esicm.org/ssc-covid19-guidelines/> (accessed April 2, 2020).
- 663 [54] Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F, Peiffer-Smadja N, C-20-15
664 DisCoVeRy French Steering Committee. Type 1 interferons as a potential
665 treatment against COVID-19. *Antiviral Res* 2020:104791.
666 <https://doi.org/10.1016/j.antiviral.2020.104791>.
- 667 [55] Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor
668 blockers in COVID-19 - CEBM n.d. [https://www.cebm.net/covid-
669 19/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-receptor-
670 blockers-in-covid-19/](https://www.cebm.net/covid-19/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-receptor-blockers-in-covid-19/) (accessed April 2, 2020).
- 671 [56] Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of
672 2019-nCoV. *Biochem Biophys Res Commun* 2020.

673 <https://doi.org/10.1016/j.bbrc.2020.02.071>.

674 [57] Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S.
675 TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by
676 TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome
677 Coronavirus Spike Protein. *J Virol* 2014;88:1293–307.
678 <https://doi.org/10.1128/jvi.02202-13>.

679 [58] Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the
680 COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-
681 Angiotensin System Blockers. *Hypertens (Dallas, Tex 1979)*
682 2020:HYPERTENSIONAHA12015082.
683 <https://doi.org/10.1161/HYPERTENSIONAHA.120.15082>.

684 [59] Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an
685 Association Between COVID-19 Mortality and the Renin-Angiotensin System-
686 a Call for Epidemiologic Investigations. *Clin Infect Dis* 2020.
687 <https://doi.org/10.1093/cid/ciaa329>.

688 [60] Yamawaki H, Futagami S, Kaneko K, Agawa S, Higuchi K, Murakami M, et
689 al. Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy
690 Improves Epigastric Pain in Early Chronic Pancreatitis and Functional
691 Dyspepsia with Pancreatic Enzyme Abnormalities. *Digestion* 2019;99:283–92.
692 <https://doi.org/10.1159/000492813>.

693 [61] Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S.
694 The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor
695 ACE2 and the cellular protease TMPRSS2 for entry into target cells. *BioRxiv*
696 2020:2020.01.31.929042. <https://doi.org/10.1101/2020.01.31.929042>.

697 [62] Blaising J, Polyak SJ, Pécheur E-I. Arbidol as a broad-spectrum antiviral: an
698 update. *Antiviral Res* 2014;107:84–94.

- 699 <https://doi.org/10.1016/j.antiviral.2014.04.006>.
- 700 [63] Fink SL, Vojtech L, Wagoner J, Slivinski NSJ, Jackson KJ, Wang R, et al. The
701 Antiviral Drug Arbidol Inhibits Zika Virus. *Sci Rep* 2018;8:8989.
702 <https://doi.org/10.1038/s41598-018-27224-4>.
- 703 [64] Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA,
704 Shoemaker CJ, et al. Arbidol and Other Low-Molecular-Weight Drugs That
705 Inhibit Lassa and Ebola Viruses. *J Virol* 2019;93.
706 <https://doi.org/10.1128/jvi.02185-18>.
- 707 [65] Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, et al. Antiviral activity of
708 arbidol against influenza A virus, respiratory syncytial virus, rhinovirus,
709 coxsackie virus and adenovirus in vitro and in vivo. *Arch Virol*
710 2007;152:1447–55. <https://doi.org/10.1007/s00705-007-0974-5>.
- 711 [66] Deng P, Zhong D, Yu K, Zhang Y, Wang T, Chen X. Pharmacokinetics,
712 metabolism, and excretion of the antiviral drug arbidol in humans. *Antimicrob*
713 *Agents Chemother* 2013;57:1743–55. <https://doi.org/10.1128/AAC.02282-12>.
- 714 [67] Glushkov RG, Gus'kova TA, Krylova LI, Nikolaeva IS. [Mechanisms of
715 arbidole's immunomodulating action]. *Vestn Ross Akad Meditsinskikh Nauk*
716 1999:36–40.
- 717 [68] Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with
718 LPV/r versus LPV/r alone against Corona Virus Disease 2019:a retrospective
719 cohort study. *J Infect* 2020. <https://doi.org/10.1016/j.jinf.2020.03.002>.
- 720 [69] Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, et al.
721 Evaluation of convalescent whole blood for treating Ebola Virus Disease in
722 Freetown, Sierra Leone. *J Infect* 2017;74:302–9.
723 <https://doi.org/10.1016/j.jinf.2016.11.009>.
- 724 [70] Wong VWS, Dai D, Wu AKL, Sung JJY. Treatment of severe acute respiratory

- 725 syndrome with convalescent plasma. *Hong Kong Med J* 2003;9:199–201.
- 726 [71] Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of
727 convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin*
728 *Microbiol Infect Dis* 2005;24:44–6. [https://doi.org/10.1007/s10096-004-1271-](https://doi.org/10.1007/s10096-004-1271-9)
729 9.
- 730 [72] Soo YOY, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KKS, et al.
731 Retrospective comparison of convalescent plasma with continuing high-dose
732 methylprednisolone treatment in SARS patients. *Clin Microbiol Infect*
733 2004;10:676–8. <https://doi.org/10.1111/j.1469-0691.2004.00956.x>.
- 734 [73] Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim
735 WS, et al. The effectiveness of convalescent plasma and hyperimmune
736 immunoglobulin for the treatment of severe acute respiratory infections of viral
737 etiology: a systematic review and exploratory meta-analysis. *J Infect Dis*
738 2015;211:80–90. <https://doi.org/10.1093/infdis/jiu396>.
- 739 [74] Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al.
740 Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV
741 Infection, Saudi Arabia. *Emerg Infect Dis* 2016;22:1554–61.
742 <https://doi.org/10.3201/eid2209.151164>.
- 743 [75] Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of
744 antibodies to SARS-associated coronavirus after recovery. *N Engl J Med*
745 2007;357:1162–3. <https://doi.org/10.1056/NEJMc070348>.
- 746 [76] Loy H, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, et al.
747 Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal
748 Cells in Attenuating Influenza A(H5N1) Virus-Associated Acute Lung Injury. *J*
749 *Infect Dis* 2019;219:186–96. <https://doi.org/10.1093/infdis/jiy478>.
- 750 [77] Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of

751 ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with
752 COVID-19 Pneumonia. *Aging Dis* 2020;11:216.
753 <https://doi.org/10.14336/ad.2020.0228>.

754 [78] Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. *Int J*
755 *Mol Sci* 2014;15:4142–57. <https://doi.org/10.3390/ijms15034142>.

756 [79] Yin K, Wang S, Zhao RC. Exosomes from mesenchymal stem/stromal cells: A
757 new therapeutic paradigm. *Biomark Res* 2019;7.
758 <https://doi.org/10.1186/s40364-019-0159-x>.

759 [80] Di Paolo N, Bocci V, Gaggiotti E. Ozone therapy. *Int J Artif Organs*
760 2004;27:168–75. <https://doi.org/10.1177/039139880402700303>.

761 [81] Infection prevention and control n.d.
762 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control)
763 [guidance/infection-prevention-and-control](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control) (accessed April 2, 2020).

764 [82] COVID-19 n.d. <https://www.ecdc.europa.eu/en/covid-19-pandemic> (accessed
765 April 2, 2020).

766 [83] Moderna’s COVID-19 vaccine could reach healthcare workers this fall |
767 FierceBiotech n.d. [https://www.fiercebiotech.com/biotech/moderna-s-covid-19-](https://www.fiercebiotech.com/biotech/moderna-s-covid-19-vaccine-could-reach-healthcare-workers-fall)
768 [vaccine-could-reach-healthcare-workers-fall](https://www.fiercebiotech.com/biotech/moderna-s-covid-19-vaccine-could-reach-healthcare-workers-fall) (accessed April 2, 2020).

769 [84] Johnson & Johnson identifies lead COVID-19 vaccine candidate n.d.
770 [https://www.drugtargetreview.com/news/58911/johnson-johnson-identifies-](https://www.drugtargetreview.com/news/58911/johnson-johnson-identifies-lead-covid-19-vaccine-candidate/)
771 [lead-covid-19-vaccine-candidate/](https://www.drugtargetreview.com/news/58911/johnson-johnson-identifies-lead-covid-19-vaccine-candidate/) (accessed April 2, 2020).

772 [85] WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial
773 Synopsis. 2020.

774 [86] Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the
775 adult respiratory distress syndrome. *Am Rev Respir Dis* 1988;138:720–3.
776 <https://doi.org/10.1164/ajrccm/138.3.720>.

- 777 [87] Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A
778 prediction rule to identify low-risk patients with community-acquired
779 pneumonia. *N Engl J Med* 1997;336:243–50.
780 <https://doi.org/10.1056/NEJM199701233360402>.
- 781 [88] Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection:
782 the perspectives on immune responses. *Cell Death Differ* 2020:1–4.
783 <https://doi.org/10.1038/s41418-020-0530-3>.
- 784 [89] Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment
785 contributes to alleviate the severity and improve the prognosis of patients with
786 novel coronavirus disease (COVID-19). *J Intern Med* 2020.
787 <https://doi.org/10.1111/joim.13063>.
- 788 [90] To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al.
789 Temporal profiles of viral load in posterior oropharyngeal saliva samples and
790 serum antibody responses during infection by SARS-CoV-2: an observational
791 cohort study. *Lancet Infect Dis* 2020;3099:1–10.
792 [https://doi.org/10.1016/S1473-3099\(20\)30196-1](https://doi.org/10.1016/S1473-3099(20)30196-1).
- 793 [91] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
794 patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*
795 2020;395:497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- 796 [92] Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-
797 19: combining antiviral and anti-inflammatory treatments. *Lancet Infect Dis*
798 2020;20:400–2. [https://doi.org/10.1016/S1473-3099\(20\)30132-8](https://doi.org/10.1016/S1473-3099(20)30132-8).
- 799 [93] Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7) n.d.
800 http://en.nhc.gov.cn/2020-03/29/c_78469.htm (accessed April 2, 2020).
- 801 [94] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al.
802 First case of 2019 novel coronavirus in the United States. *N Engl J Med*

803 2020;382:929–36. <https://doi.org/10.1056/NEJMoa2001191>.

804 [95] NIH clinical trial of investigational vaccine for COVID-19 begins | National
805 Institutes of Health (NIH) n.d. [https://www.nih.gov/news-events/news-](https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins)
806 [releases/nih-clinical-trial-investigational-vaccine-covid-19-begins](https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins) (accessed
807 April 2, 2020).

808 [96] Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease
809 (COVID-19) in the Healthcare Setting - Full Text View - ClinicalTrials.gov
810 n.d. <https://clinicaltrials.gov/ct2/show/NCT04303507> (accessed April 2, 2020).

811 [97] Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and
812 diagnosis of COVID-19. *J Pharm Anal* 2020.
813 <https://doi.org/10.1016/j.jpha.2020.03.001>.

814 [98] Cepheid | Xpert® Xpress SARS-CoV-2 has received FDA Emergency Use
815 Authorization n.d. <https://www.cepheid.com/coronavirus> (accessed April 2,
816 2020).


817 [99] Detect COVID-19 in as Little as 5 Minutes | Abbott Newsroom n.d.
818 [https://www.abbott.com/corpnewsroom/product-and-innovation/detect-covid-](https://www.abbott.com/corpnewsroom/product-and-innovation/detect-covid-19-in-as-little-as-5-minutes.html)
819 [19-in-as-little-as-5-minutes.html](https://www.abbott.com/corpnewsroom/product-and-innovation/detect-covid-19-in-as-little-as-5-minutes.html) (accessed April 4, 2020).

820 [100] Report of the WHO-China Joint Mission on Coronavirus Disease 2019
821 (COVID-19) n.d. [https://www.who.int/publications-detail/report-of-the-who-](https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))
822 [china-joint-mission-on-coronavirus-disease-2019-\(covid-19\)](https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)) (accessed April 2,
823 2020).

824

825

826 **Figures:**
 827 Figure 1. Systematic review Flow Chart.



828
829

830

831

832

833

834

835

836

837

838


839

840

841

842 Figure 2. Currently tested therapeutic molecules targeting different steps of SARS-
 843 CoV-2 life cycle.

844



845

846

847

848

849

850

851

852

853

854

855


856

857

858 Figure 3. General and supportive therapeutic interventions tested for novel coronavirus
859 disease (COVID-19).

860

861



862

863

864

865

866

867

868

869


870

871

872


873

874 Figure 4. Number of trials reported by the median of the total number of planned
 875 inclusions per trial for the most common treatments.



876

877 Figure 5. Number of trials per total number of planned inclusions for the ten most
 878 frequently assessed treatments.



879

880 *Note: The size of the circle corresponds to the addition of the total numbers of*
 881 *planned inclusions for all trials evaluating one of the treatments*

882

883 **Tables:**

884 Table 1. Treatment interventions currently being evaluated for the novel coronavirus

885 disease (COVID-19) globally.

Therapeutic Intervention	Countries	No. of trials being tested	No. of RCTs (% of trials per intervention)	Other agents used in combination
TCMs	China	92	61 (66.3)	IFN α , LPV/r, Ribavirin, Chloroquine, Umifenovir, Ulinastatin
Antimalaria drugs (hydroxychloroquine, chloroquine, dihydroartemisinin piperazine)	China, France, Germany, Mexico, Norway, Spain, Brazil, Canada	34	27 (79.4)	Azithromycin, LPV/r, DRV/r or c, Favipiravir, Oseltamivir, Umifenovir, IFN α
Lopinavir \pm ritonavir (LPV \pm r)	China, Thailand, Hong Kong, United Kingdom, Europe, South Korea, Canada	32	31 (96.8)	Chloroquine, IFN α , IFN β , Navaferon, Thymosin a1, FTC/TAF, Ribavirin, Ebastine, Oseltamivir, Favipiravir, TCM
Cell therapy	China, USA, Brazil, Jordan	30	18 (60)	Ruxolitinib
Interferon (IFN α , IFN α 2 β , IFN β , rSIFN-co)	China, UK, Hong Kong, Europe	22	22 (100)	Umifenovir, Dihydroartemisinin piperazine, TCM, Bromhexine, Favipiravir, LPV/r, Ribavirin, Ebastine, Danoprevir/r, Thalidomide, Methylprednisolone, TTF2
Anti-IL-6 mAb (Tocilizumab, Sarilumab)	China, Italy, France, Switzerland, Denmark, USA, Canada, Global	14	9 (64.3)	Favipiravir, Adalimumab
Dietary/Supportive	China, Egypt	13	10 (76.9)	N/A
Corticosteroids	China, UK, Italy	11	9 (81.8)	IFN α Umifenovir, Thalidomide
Umifenovir	China	11	11 (100)	Novaferon, IFN α , IFN α 2 β , Dihydroartemisinin piperazine, Bromhexine, Favipiravir, Thalidomide, Methylprednisolone

Convalescent plasma	China, Italy	10	7 (70)	N/A
Adjuvant Device	China	9	3 (33.3)	N/A
Favipiravir	China, Thailand	8	8 (100)	Tocilizumab, Bromhexine, IFN α , Umifenovir, (Hydroxy)chloroquine, LPV/r, DRV/r
Remdesivir	Global, Europe, USA, China	8	7 (87.5)	Hydroxychloroquine
Ventilation/ Oxygenation strategies	China	7	0 (0)	N/A
Macrolides (azithromycin, carrimycin)	China, Brazil, Denmark	4	4 (100)	Hydroxychloroquine
Inhaled Gases	China, USA, Italy	4	4 (100)	N/A
JAK inhibitors (Jakotinib, Ruxolitinib, Baricitinib)	China, Italy, Canada	4	2 (50)	Cell therapy, Ritonavir
ACE inhibitor / ARBs	China, USA	3	2 (66.7)	N/A
Azvudine	China	3	1 (33.3)	N/A
Danoprevir/ritonavir	China	3	3 (100)	IFN
Darunavir/cobicistat (DRV/r)	China, Thailand	3	3 (100)	Thymosin a1, Oseltamivir, Hydroxychloroquine, Favipiravir
Pirferidone	China	3	3 (100)	N/A
Anti-PD-1 mAb	China	3	3 (100)	N/A
Oseltamivir	Thailand, China	3	3 (100)	Hydroxychloroquine, DRV/r, LPV/r
Thymosin a1	China	3	3 (100)	DRV/c, LPV/r
Adalimumab	China	2	2 (100)	Tocilizumab
Bevacizumab	China, Italy	2	1 (50)	N/A
Colchicine	Italy, Canada	2	2 (100)	N/A
Novafeon	China	2	2 (100)	LPV/r, Umifenovir
Ribavirin	China, Hong Kong	2	2 (100)	IFN, LPV/r
Thalidomide	China	2	2 (100)	IFN α , Umifenovir, Methylprednisolone
Ulinastatin	China	2	1 (50)	TCM

ASC09/ritonavir	China	2	2 (100)	N/A
Intravenous	China	2	2 (100)	N/A
Immunoglobulin				
Acetylcysteine	China	1	1 (100)	N/A
Antiviral peptide LL-37	China	1	0 (0)	N/A
Baloxavir Marboxil	China	1	1 (100)	N/A
Bismuth potassium	China	1	1 (100)	N/A
Bronchoscopic alveolar lavage	China	1	0 (0)	N/A
CD24Fc	USA	1	1 (100)	N/A
Dipyridamole	China	1	1 (100)	N/A
Ebastine	China	1	1 (100)	IFN α , LPV/r
Eculizumab	N/A	1	0 (0)	N/A
Enoxaparin	China	1	1 (100)	N/A
Escin	Italy	1	0 (0)	N/A
Fingolimod	China	1	0 (0)	N/A
FTC/TAF	China	1	1 (100)	LPV/r
hrIL-2	China	1	1 (100)	N/A
Inactivated mycobacterial vaccine	China	1	1 (100)	N/A
Itraconazole	Belgium	1	1 (100)	N/A
Ixekizuman	China	1	1 (100)	IFN α , Ribavirin, Chloroquine, LPV/r, Umifenovir
Leflunomide	China	1	1 (100)	N/A
M1	China	1	1 (100)	N/A
Polyinosinic/ polycytidylic acid	China	1	1 (100)	N/A
rhG-CSF	China	1	1 (100)	N/A
Sargramostin (GM-CSF)	Belgium	1	1 (100)	N/A
Sildenafil	China	1	0 (0)	N/A
Siltuximab	Italy	1	0 (0)	N/A
Suramin	China	1	0 (0)	N/A
T89	N/A	1	1 (100)	N/A

TFF-2	China	1	1 (100)	IFN- κ
TMPRSS2 inhibitor (camostat mesylate)	Denmark	1	1 (100)	N/A
Tranilast	China	1	1 (100)	N/A
VIP	USA, Israel	1	1 (100)	N/A
vMIP	China	1	0 (0)	N/A
Meplazumab (anti- CD147)	China	1	1 (100)	N/A
Sodium Aescinate	China	1	1 (100)	N/A
Triazavirin	China	1	1 (100)	N/A

ACE: Angiotensin converting enzyme, Anti-PD-1 mAb: Anti Program Cell Death Protein-1 monoclonal antibody, ARBs: Angiotensin II receptor blockers, CD24Fc: CD24 extracellular domain-IgG1 Fc domain recombinant fusion protein, DRV/r or c: Darunavir/ritonavir or cobicistat, FTC/TAF: Emtricitabine/Tenofovir alafenamide, GM-CSF: Granulocyte Macrophage-Colony Stimulating Factor, hrIL-2: human recombinant interleukin 2, IFN α : Interferon alpha, IFN β : Interferon beta, IFN κ : Interferon kappa, IL: Interleukin, JAK: Janus Kinases, LPV/r: Lopinavir/ritonavir, M1: Type I Macrophage, N/A: Not applicable, RCTs: Randomised controlled trials, rhG-CSF: recombinant human Granulocyte-Colony Stimulating Factor, TCMs: Traditional Chinese Medicines, TMPRSS2: Transmembrane Protease Serine 2, TTF-2: Transcription Termination Factor 2, UK: United Kingdom, USA: United States of America, VIP: Vasoactive Intestinal Peptide, vMIP: viral Macrophage Inflammatory Protein.

886

887

888 Table 2. Prevention interventions currently being evaluated for the novel coronavirus
 889 disease (COVID-19) globally.

Prevention intervention	Countries	No. of trials being tested	No. of RCTs (% of trials per intervention)	Other agents used in combination
TCMs	China	10	3 (30)	N/A
Antimalaria Drugs	China, USA, Mexico, UK, Spain	6	6 (100)	Umifenovir, DRV/c
Vaccine	USA, China	4	0 (0)	N/A
Health education	China, Hungary	3	2 (66.7)	TCM
IFN α 1 β	China	2	0 (0)	Thymosin a1
Darunavir/cobicistat	Spain	1	1 (100)	Chloroquine
Lopinavir/ritonavir	Canada	1	1 (100)	N/A
Mask	Canada	1	1 (100)	N/A
PUL-042	USA	1	1 (100)	N/A
Thymosin a1	China	1	0 (0)	IFN α 1 β
Umifenovir	China	1	1 (100)	Hydroxychloroquine

DRV/c: Darunavir/cobicistat, IFN α : Interferon alpha, LPV/r: Lopinavir/ritonavir, N/A: Not applicable, RCTs: Randomised controlled trials, TCMs: Traditional Chinese Medicines, UK: United Kingdom, USA: United States of America.

890

891

892 Table 3. Description of the clinical trials registered for the treatment and prevention of
 893 COVID-19.

Study characteristics	Treatment studies	Prevention studies
	N = 198 (%)	N = 16 (%)
Study phase		
Phase I	9 (5)	3 (19)
Phase II*	31 (16)	2 (13)
Phase III**	35 (18)	6 (38)
Phase IV	40 (20)	1 (6)
Unspecified	83 (42)	4 (25)
Study design		
Randomised	150 (76)	10 (63)
Non-randomised	21 (11)	3 (19)
Single-arm	27 (14)	3 (19)
Blinding		
Double-blind	31 (16)	6 (38)
Single-blind	16 (8)	2 (13)
Open-label	73 (37)	5 (31)
Non-applicable†	29 (15)	3 (19)
Unspecified	49 (25)	0 (0)
Total number of planned inclusions		
<50	62 (31)	1 (6)
50-100	41 (21)	0 (0)
100-150	32 (16)	3 (19)
150-200	9 (5)	0 (0)
200-250	15 (8)	1 (6)
≥250	39 (20)	11 (69)
Primary endpoint		
Clinical	128 (65)	13 (81)
Virological	39 (20)	2 (13)
Radiological	19 (10)	0 (0)
Immunological/biological	12 (6)	1 (6)

*Including phase I/II trials; **Including phase II/III trials; †: Single-arm or factorial trials.

